Marinomed Biotech files for court restructuring proceedings without self-administration

• Marinomed Biotech filed for a court-led restructuring proceeding without self-administration.
• Raiffeisen Bank International terminated its market-making liquidity services contract with immediate effect.
• The stock may see thinner trading liquidity and wider bid-ask spreads, though it remains tradable on its venues.
• The company postponed publication of its H1 2026 financial report, previously scheduled for Sept. 16, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marinomed Biotech AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2370028_de) on July 22, 2026, and is solely responsible for the information contained therein.